Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.83 |
| ▸ | PGR | P06401 | 5/20 | 0.83 |
| ▸ | AR | P10275 | 5/20 | 0.83 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.83 |
| ▸ | CNR1 | P21554 | 1/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214334 | 1.00 | NR3C1 (0.83) | NR3C1PGRARNR3C2CNR1 | |
| SCHEMBL17679404 | 1.00 | NR3C1 (0.83) | NR3C1PGRARNR3C2CNR1 | |
| SCHEMBL4226974 | 1.00 | NR3C1 (0.83) | NR3C1PGRARNR3C2CNR1 | |
| SCHEMBL4360516 | 0.95 | NR3C1 (0.85) | NR3C1PGRARNR3C2CNR1 | |
| SCHEMBL15225995 | 0.94 | NR3C1 (0.84) | NR3C1PGRARNR3C2CNR1 | |
| SCHEMBL15226108 | 0.94 | NR3C1 (0.81) | NR3C1PGRARNR3C2CNR1 | |
| SCHEMBL13928704 | 0.94 | NR3C1 (0.81) | NR3C1PGRARNR3C2CNR1 | |
| SCHEMBL4213208 | 0.94 | NR3C1 (0.81) | NR3C1PGRARNR3C2CNR1 | |
| SCHEMBL15225842 | 0.92 | NR3C1 (0.79) | NR3C1PGRARNR3C2CNR1 | |
| SCHEMBL15225892 | 0.92 | NR3C1 (0.79) | NR3C1PGRARNR3C2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004133-B1 | METHODS FOR TREATMENT OF INFLAMMATORY CONDITIONS USING S-[4-(3-FLUORO-3-METHYLBUTYRYLOXY) BUT-2-YNYL]6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(FURAN-2-YL) CARBONYLOXY-11BETA -HYDROXY-16ALPHA-METHYL-3-OXOANDROSTA-1,4-DIENE-17BETA -CARBOTHIOATE. | SUN PHARMA ADVANCED RES CO LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| US-9458187-B2 | Methods for treatment of inflammatory conditions using S-[4-(3-fleuro-3-methylbutyryloxy)but-2-ynyl]6α, 9α-difluoro-17α-(furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2016-10-04 | — | — | US | disclosed |
| US-9458187-B2 | Methods for treatment of inflammatory conditions using S-[4-(3-fleuro-3-methylbutyryloxy)but-2-ynyl]6α, 9α-difluoro-17α-(furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2016-10-04 | — | — | US | disclosed |
| US-20160102117-A1 | METHODS FOR TREATMENT OF INFLAMMATORY CONDITIONS USING S-[4-(3- FLUORO-3-METHYLBUTYRYLOXY) BUT-2-YNYL] 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(FURAN-2-YL) CARBONYLOXY-11BETA -HYDROXY-16ALPHA-METHYL-3-OXOANDROSTA-1,4-DIENE-17BETA - CARBOTHIOATE | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| US-20160102117-A1 | METHODS FOR TREATMENT OF INFLAMMATORY CONDITIONS USING S-[4-(3- FLUORO-3-METHYLBUTYRYLOXY) BUT-2-YNYL] 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(FURAN-2-YL) CARBONYLOXY-11BETA -HYDROXY-16ALPHA-METHYL-3-OXOANDROSTA-1,4-DIENE-17BETA - CARBOTHIOATE | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| WO-2014192027-A1 | METHODS FOR TREATMENT OF INFLAMMATORY CONDITIONS USING S-[4-(3-FLUORO-3-METHYLBUTYRYLOXY) BUT-2-YNYL] 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(FURAN-2-YL) CARBONYLOXY-11BETA -HYDROXY-16ALPHA-METHYL-3-OXOANDROSTA-1,4-DIENE-17BETA -CARBOTHIOATE. | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2014-12-04 | — | — | WO | disclosed |
| US-8785425-B2 | 11β-hydroxyandrosta-4-ene-3-ones | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. | 2014-07-22 | — | — | US | disclosed |
| US-8785425-B2 | 11β-hydroxyandrosta-4-ene-3-ones | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. | 2014-07-22 | — | — | US | disclosed |
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMA ADVANCE RESEARCH COMPANY (IN) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | HSD11B1, HSD3B1, HSD3B2 | NR3C1 37/4885PGR 146/4885AR 22/4885 |
| US-20160102117-A1 | METHODS FOR TREATMENT OF INFLAMMATORY CONDITIONS USING S-[4-(3- FLUORO-3-METHYLBUTYRYLOXY) BUT-2-YNYL] 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(FURAN-2-YL) CARBONYLOXY-11BETA -HYDROXY-16ALPHA-METHYL-3-OXOANDROSTA-1,4-DIENE-17BETA - CARBOTHIOATE | HSD17B11, HSD17B7, CYP17A1 | NR3C1 16/4885PGR 1066/4885AR 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.